Alisertib (MLN8237) in Participants With Ovarian, Fallopian Tube or Peritoneal Cancer Preceded by Phase 1 Study of MLN8237 Plus Paclitaxel Treatment of Ovary or Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Ovarian Carcinoma|Fallopian Tube Cancer|Peritoneal Cancer|Breast Carcinoma
Interventions: DRUG: Alisertib|DRUG: Paclitaxel
Sponsor: Millennium Pharmaceuticals, Inc.